BLFS (BioLife Solutions) Other Stockholders Equity: $0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BLFS BioLife Solutions Inc BLFS
73 GF Score
Price $35.07
GF Value $29.92
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is BioLife Solutions Other Stockholders Equity?

BioLife Solutions BLFS +0.70% 73 Other Stockholders Equity is $0.0 Mil as of Jun. 2026. GuruFocus rates BLFS with a GF Score™ of 73/100 and a GF Value™ of $29.92 (Modestly Overvalued). The stock has 8 warning signs investors should review.

BioLife Solutions's Other Stockholders Equity for the quarter that ended in Jun. 2026 was $0.0 Mil.

BioLife Solutions's annual Other Stockholders Equity declined from Dec. 2023 ($0.0 Mil) to Dec. 2024 ($0.0 Mil) but then stayed the same from Dec. 2024 ($0.0 Mil) to Dec. 2025 ($0.0 Mil).

BioLife Solutions Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for BioLife Solutions's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioLife Solutions Other Stockholders Equity Chart

BioLife Solutions Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.00 -0.00 0.00 0.00 0.00

BioLife Solutions Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 0.00 0.00 0.00 0.00
BLFS
73GF Score
BioLife Solutions Inc BLFS
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioLife Solutions Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $0.0 Mil mean?
BioLife Solutions (BLFS) has a Other Stockholders Equity of $0.0 Mil as of Jun. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on BioLife Solutions and its competitors.
Is BioLife Solutions' Other Stockholders Equity too high?
BioLife Solutions' current Other Stockholders Equity is $0.0 Mil. Overall, BioLife Solutions has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BioLife Solutions' Other Stockholders Equity compare to AZTA and KMTS?
BioLife Solutions' Other Stockholders Equity of $0.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Medical Devices & Instruments company?
A good Other Stockholders Equity depends on the Medical Devices & Instruments industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on BioLife Solutions and its competitors. BioLife Solutions's current Other Stockholders Equity is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLife Solutions stock overvalued right now?
Based on GuruFocus' analysis, BioLife Solutions (BLFS) is currently considered Modestly Overvalued. The stock's GF Value™ is $29.92, compared to a current price of $35.07 — trading 17.2% above its estimated fair value. The current Other Stockholders Equity is $0.0 Mil. BioLife Solutions' overall GF Score™ is 73/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For BioLife Solutions (BLFS), the current Other Stockholders Equity is $0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioLife Solutions (BLFS) Overvalued in 2026?

Based on GuruFocus' analysis, BioLife Solutions stock appears to be overvalued. The current stock price of $35.07 is trading 17.2% above its estimated GF Value™ of $29.92. GuruFocus considers BioLife Solutions to be Modestly Overvalued.

Key valuation signals for BLFS:

  • Other Stockholders Equity: $0.0 Mil
  • GF Value™: $29.92 vs. price of $35.07 (17.2% above fair value)
  • GF Score™: 73/100 with 8 warning signs

No single metric tells the full story. See the BLFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioLife Solutions Business Description

Other Exchanges BJX1:Germany
Address 3303 Monte Villa Parkway, Suite 310, Bothell, WA, USA, 98021
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
73GF Score

Get the complete analysis for BLFS

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$35.07
Price
$29.92
GF Value